NEW YORK (GenomeWeb) – Cepheid's new CLIA-waived influenza test and multi-module instrument are intended for use at the point of care, putting them in competition with a handful of other systems in the rapid molecular diagnostic test space for flu.
Cepheid's CLIA-Waived Multi-Module System Ups Competition in POC MDx; Barriers to Uptake Linger
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.